

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

HT-1080

RRID:CVCL_0317

Type: Cell Line

Proper Citation

RRID:CVCL_0317

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0317

Proper Citation: RRID:CVCL_0317

Description: Cell line HT-1080 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Fibrosarcoma

Defining Citation: [PMID:375235](#), [PMID:3335022](#), [PMID:3413074](#), [PMID:3558490](#), [PMID:3986962](#), [PMID:4132053](#), [PMID:6304521](#), [PMID:6538202](#), [PMID:6652615](#), [PMID:11416159](#), [PMID:11668190](#), [PMID:12068308](#), [PMID:17254797](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22282976](#), [PMID:22460905](#), [PMID:24726063](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26351324](#), [PMID:26368816](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Caution: This cell line is considered by some researchers to represent a dedifferentiated chondrosarcoma due to the presence of an IDH1 mutation (PubMed=26368816)., Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HT-1080

Synonyms: Ht-1080, HT 1080, HT1080, HT 1080.T

Cross References: BTO:BTO_0001282, CLO:CLO_0004266, CLO:CLO_0004276, EFO:EFO_0002059, MCCL:MCC:0000210, CLDB:cl1735, CLDB:cl1736, CLDB:cl1737, CLDB:cl1738, CLDB:cl1740, CLDB:cl1741, CLDB:cl1742, CLDB:cl4913, ABM:T8971, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-121, ATCC:CRL-7951, BCRC:60037, BCRJ:0110, BioGRID_ORCS_Cell_line:279, BioSample:SAMN01821563, BioSample:SAMN01821634, BioSample:SAMN01821685, BioSample:SAMN01821731, BioSample:SAMN03471913, BioSample:SAMN10987635, cancercellines:CVCL_0317, CCRID:1101HUM-PUMC000070, CCRID:3101HUMTCHu170, CCRID:4201HUM-CCTCC00105, CCTCC:GDC0105, Cell_Model_Passport:SIDM00828, ChEMBL-Cells:ChEMBL3308396, ChEMBL-Targets:ChEMBL614580, CLS:300216, Cosmic:716177, Cosmic:716188, Cosmic:724819, Cosmic:907064, Cosmic:912000, Cosmic:1045409, Cosmic:1067221, Cosmic:1933190, Cosmic:2009505, Cosmic:2301553, Cosmic:2307731, Cosmic:2560245, Cosmic:2764533, Cosmic-CLP:907064, DepMap:ACH-000054, DSMZ:ACC-315, DSMZCellDive:ACC-315, ECACC:85111505, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS039VHD, ENCODE:ENCBS225AAA, ENCODE:ENCBS512AAA, ENCODE:ENCBS513AAA, ENCODE:ENCBS617SGR, ENCODE:ENCBS688VJF, ENCODE:ENCBS798NML, ENCODE:ENCBS816VMN, ENCODE:ENCBS937RAY, FANTOM5_SSTAR:10758-110E2, GDSC:907064, GEO:GSM185089, GEO:GSM185090, GEO:GSM256074, GEO:GSM256075, GEO:GSM256076, GEO:GSM256077, GEO:GSM256078, GEO:GSM256079, GEO:GSM256080, GEO:GSM256081, GEO:GSM256082, GEO:GSM256083, GEO:GSM256084, GEO:GSM256085, GEO:GSM256086, GEO:GSM256087, GEO:GSM256088, GEO:GSM256089, GEO:GSM256090, GEO:GSM256091, GEO:GSM256092, GEO:GSM256093, GEO:GSM256094, GEO:GSM256095, GEO:GSM256096, GEO:GSM256097, GEO:GSM256098, GEO:GSM256099, GEO:GSM256100, GEO:GSM256101, GEO:GSM256102, GEO:GSM256103, GEO:GSM256104, GEO:GSM256105, GEO:GSM256106, GEO:GSM256107, GEO:GSM256108, GEO:GSM256109, GEO:GSM256110, GEO:GSM256111, GEO:GSM256112, GEO:GSM256113, GEO:GSM256114, GEO:GSM827307, GEO:GSM887136, GEO:GSM888207, GEO:GSM1669908, GEO:GSM1676302, GEO:GSM1701637, GEO:GSM3585511, GEO:GSM3585512, GEO:GSM3585513, GEO:GSM3585514, IARC_TP53:21378, IBRC:C10104, ICLC:HTL98016, IGRhCellID:HT1080, IZSLER:BS TCL 27, JCRB:IFO50354, JCRB:JCRB9113, KCB:KCB 2013029YJ, KCLB:10121, LiGeA:CCL_463, LINCS_LDP:LCL-1435, Lonza:744, NCBI_Iran:C437, PharmacDB:HT1080_625_2019, PRIDE:PXD030304, Progenetix:CVCL_0317, PubChem_Cell_line:CVCL_0317, RCB:RCB1956, TKG:TKG 0202, TOKU-E:1963, Wikidata:Q5636047

ID: CVCL_0317

Record Creation Time: 20220427T220617+0000

Record Last Update: 20260905T180809+0000

Ratings and Alerts

No rating or validation information has been found for HT-1080.

Warning: Discontinued: ATCC; CRL-7951

Caution: This cell line is considered by some researchers to represent a dedifferentiated chondrosarcoma due to the presence of an IDH1 mutation (PubMed=26368816)., Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: RCB; RCB1956
Caution: This cell line is considered by some researchers to represent a dedifferentiated chondrosarcoma due to the presence of an IDH1 mutation (PubMed=26368816)., Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2382 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Honda R, et al. (2026) The E3 ubiquitin ligase UBR5 promotes ubiquitylation and degradation of the chromatin regulator ATAD2. FEBS letters, 600(9), 1330.

Kolak A, et al. (2026) miR-940 suppresses ferroptosis by controlling expression of key regulatory genes. bioRxiv : the preprint server for biology.

Yang Q, et al. (2026) MSH6 regulates cGAS activity in antiviral and antitumor signaling pathways by governing its cytosolic/nuclear distribution. Cell reports, 45(3), 117059.

Zhou C, et al. (2026) Discovery and Optimization of Novel Carbazole-Based Ferroptosis Inhibitors. Chemistry & biodiversity, 23(6), e71430.

Zanella E, et al. (2026) Damage-induced i-loops generate eccDNA from repetitive elements. Molecular cell, 86(10), 1856.

Wolhuter K, et al. (2026) Multi-omic analysis of human PHACTR1 signaling networks. Communications biology, 9(1), 265.

Yu H, et al. (2026) p300 Degradation by the p53-SIAH1 Axis Relieves TBK1 Acetylation to Enhance Innate Antiviral Immunity. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e76101.

Dutta S, et al. (2026) MMP9 drives cancer invasion by mediating integrin membrane trafficking and stabilization. *The FEBS journal*.

Yang T, et al. (2026) Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(42), e20252.

Ortega R, et al. (2026) PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs. *Nucleic acids research*, 54(1).

Caire R, et al. (2026) A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer. *Cell*, 189(12), 3701.

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. *Cell reports. Medicine*, 7(4), 102695.

Lee SJ, et al. (2026) Hypoxia restores the acidosis-induced inhibition of cancer cell dissemination. *Cell reports*, 45(2), 116970.

Chen B, et al. (2026) BRD4-mediated ER membrane contact creates functionally distinct mitochondrial subtypes. *Molecular cell*, 86(5), 917.

Krumwiede L, et al. (2026) MORC3 represses a tandem repeat enhancer to regulate interferon. *The EMBO journal*, 45(14), 5130.

Yasuda T, et al. (2026) Disrupted mitochondrial dynamics activate RNA-sensing innate immunity through mitochondrial RNA release. *Cell reports*, 45(7), 117607.

Uno S, et al. (2026) Assessment of mitochondrial lipid peroxidation in cells and zebrafish using a targeted mass spectrometry probe. *Cell chemical biology*.

Qiao M, et al. (2026) ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(16), e13310.

Gruber DR, et al. (2026) Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. *Molecular cancer therapeutics*, 25(3), 457.

Nebenfuehr B, et al. (2026) Uncovering genetic interactions in the DNA repair network in response to endogenous damage and ionizing radiation. *Cell reports*, 45(1), 116850.